|
1）Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958; 18: 533-47
|
|
|
|
2）Tuder RM, Groves B, Voelkel NF, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994; 144: 275-85
|
|
|
|
|
|
3）Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35: 7335-42
|
|
|
|
|
|
4）Prunotto M, Budd DC, Moll S, et al. Epithelial-mesenchymal crosstalk alteration in kidney fibrosis. J Pathol. 2012; 228: 131-47
|
|
|
|
|
|
5）Pain M, Bermudez O, Magnan A, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev. 2014; 23: 118-30
|
|
|
|
|
|
6）Arciniegas E, Sutton AB, Schor AM, et al. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci. 1992; 103 (Pt 2): 521-9
|
|
|
|
|
|
7）Arciniegas E, Frid MG, Stenmark KR, et al. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L1-8
|
|
|
|
|
|
8）Zeisberg EM, Tarnavski O, Kalluri R, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007; 13: 952-61
|
|
|
|
|
|
9）Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008; 99: 1375-9
|
|
|
|
|
|
10）Hashimoto N, Phan SH, Hasegawa Y, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010; 43: 161-72
|
|
|
|
|
|
11）Newman JH, Wheeler L, Loyd JE, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001; 345: 319-24
|
|
|
|
|
|
12）Mihira H, Suzuki HI, Watabe T, et al. TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. J Biochem. 2012; 15: 145-56
|
|
|
|
|
|
13）Ghosh AK, Nagpal V, Vaughan DE, et al. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cell Signal. 2012; 24: 1031-6
|
|
|
|
|
|
14）Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011; 121: 233-51
|
|
|
|
|
|
15）Reynolds AM, Holmes MD, Reynolds PN, et al. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J. 2012; 39: 329-43
|
|
|
|
|
|
16）West J, Fagan K, Rodman DM, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004; 94: 1109-14
|
|
|
|
|
|
17）Long L, Crosby A, Morrell NW, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009; 119: 566-76
|
|
|
|
|
|
18) Ogo T, Chowdhury HM, Nasim MT, et al. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013; 48: 733-41
|
|
|
|
|
|
19）Hong KH, Lee YJ, Oh SP, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008; 118: 722-30
|
|
|
|
|
|
20）Li Z, Jimenez SA. Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum. 2011; 63: 2473-83
|
|
|
|
|
|
21）Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med. 2010; 152: 159-66
|
|
|
|
|
|
22）Sakao S, Taraseviciene-Stewart L, Voelkel NF, et al. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 2005; 19: 1178-80
|
|
|
|
|
|
23）Sakao S, Taraseviciene-Stewart L, Voelkel NF, et al. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. Am J Physiol Lung Cell Mol Physiol. 2006; 291: L362-8
|
|
|
|
|
|
24）Sakao S, Kuriyama T, Voelkel NF, et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells. FASEB J. 2007; 21: 3640-52
|
|
|
|
|
|
25）Taraseviciene-Stewart L, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001; 15: 427-38
|
|
|
|
|